Impact BioMedical Inc. (IBO)
NYSEAMERICAN: IBO · Real-Time Price · USD
5.14
+0.37 (7.76%)
Nov 13, 2026, 4:00 PM EST - Market closed

Impact BioMedical Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
0.040.03--0.05-
Revenue Growth
52.00%-----
Gross Profit
-0.39-0.39--0.05-
Operating Income
-4.8-4.27-3.4-4.03-3.4-3.19
Net Income
1.61-11.84-24.71-4.34-7.05-1.3
Earnings Per Share
0.18-4.80-29.03-0.91-1.26-0.23
EPS Growth
------

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
0.0202000.05
Total Debt
--8.8812.079.9912.52
Net Cash (Debt)
0.020-6.88-12.07-9.99-12.48
Net Cash Growth
------
Net Cash Per Share
0.000.00-8.07-2.53-1.79-2.23

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
0.12-1.89-2.85-2.85-2.24-2.03
Capital Expenditures
----0.02-0.28-
Free Cash Flow
0.12-1.89-2.85-2.87-2.52-2.03
Free Cash Flow Growth
------

Margins

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
----100.00%-
Operating Margin
-12621.05%-13343.75%---6808.00%-
Pretax Margin
-2560.53%-45156.25%---15752.00%-
Profit Margin
4247.37%-36993.75%---14102.00%-
FCF Margin
305.26%-5906.25%---5036.00%-

Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
1155.661651.05----